Cambrex Corp. (CBM1)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Steven M. Klosk
Employees:
1,732
ONE MEADOWLANDS PLZ, E RUTHERFORD, NJ 07073
2018043000

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates. The company was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in December 1981 and is headquartered in East Rutherford, NJ.

Data derived from most recent annual or quarterly report
Market Cap 2.019 Billion Shares Outstanding33.66 Million Avg 30-day Volume 282.958 Thousand
P/E Ratio54.8464 Dividend Yield0.0 EPS1.05
Price to Revenue3.2583 Debt to Equity0.7287 EBITDA147.191 Million
Price to Book Value2.985 Operating Margin14.6169 Enterprise Value2.429 Billion
Current Ratio2.372 EPS Growth-0.721 Quick Ratio1.066
1 Yr BETA 0.8461 52-week High/Low 0.0 / Profit Margin5.9407
Operating Cash Flow Growth11.7872 Altman Z-Score2.785 Free Cash Flow to Firm -152.28 Million
View SEC Filings from CBM1 instead.

View recent insider trading info

Funds Holding CBM1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CBM1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HARRIGAN KATHRYN

  • Director
No longer subject to file 2019-12-04 0

GLASSELL CLAES

  • Director
No longer subject to file 2019-12-04 0

KLOSK STEVEN M PRESIDENT & CEO

  • Officer
  • Director
No longer subject to file 2019-12-04 0

KAUFTHAL ILAN

  • Director
No longer subject to file 2019-12-04 0

SARGEN GREGORY CFO & EVP, CORP. DEV.

  • Officer
No longer subject to file 2019-12-04 0

HAMPL BERNHARD

  • Director
No longer subject to file 2019-12-04 0

CAVANAGH SHAWN EVP & COO

  • Officer
No longer subject to file 2019-12-04 0

BROWN GREGORY B

  • Director
No longer subject to file 2019-12-04 0

YANAI SHLOMO

  • Director
No longer subject to file 2019-12-04 0

HANLEY SAMANTHA SVP, GENERAL COUNSEL

  • Officer
No longer subject to file 2019-12-04 0

GRABOWSKY LOUIS J.

  • Director
No longer subject to file 2019-12-04 0

DONNELLY-BRIENZA DOROTHY A SVP & CHRO

  • Officer
No longer subject to file 2019-12-04 0

VADAKETH TOM GEORGE EVP & CFO

  • Officer
0 2018-08-20 0

DIXON ROSINA B

  • Director
84,226 2018-02-12 0

HENDRIX LEON J JR

  • Director
67,301 2017-06-06 0

TOMBROS PETER G

  • Director
24,029 2017-04-27 0

KORB WILLIAM B

  • Director
20,562 2016-07-11 0

MAGNINI ALDO

  • MANAGIN DIRECTOR-PROFARMACO
0 2015-02-12 0

HASKEL WILLIAM M. SENIOR VICE PRESIDENT

  • Officer
0 2014-11-13 0

WINSCHEL JAMES F JR

  • Director
1,350 2014-08-05 0

RUSSOLO PAOLO

  • PRESIDENT, CAMBREX PROFARMACO
73,518 2013-11-22 0

MILLER JOHN R

  • Director
35,306 2013-11-11 0

BETHUNE DAVID R

  • Director
21,116 2012-04-25 0

HALEY ROY W

  • Director
1,356 2009-12-31 0

ZACHARA F. MICHAEL VICE PRESIDENT

  • Officer
0 2009-10-28 0

MACK JAMES A PRESIDENT, CEO & CHAIRMAN

  • Officer
190,734 2008-01-24 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments